MediGene AG Congratulates the Chairman of its Supervisory Board, Professor Dr. Ernst-Ludwig Winnacker, on the Robert Koch Gold Medal

Martinsried/Munich, November 11, 2011. MediGene AG announces that the company’s co-founder and Chairman of the Supervisory Board, Professor Dr. Ernst-Ludwig Winnacker, Secretary General of the international “Human Frontier Science Program” Organization (HFSP), Strasbourg, France, was awarded the Robert Koch Medal in Gold today. The Robert Koch Medal in Gold, one of the most prestigious awards in medicine, is presented annually by the Robert Koch Foundation under the patronage of the German Federal President to honor outstanding lifetime scientific achievements.

Dr. Frank Mathias, Chief Executive Officer of MediGene AG: “On behalf of MediGene’s executive and supervisory boards and employees, I congratulate Professor Winnacker on this renowned award. We are proud of our Chairman of the Supervisory Board, and grateful that he accompanies and supports MediGene’s development with his outstanding expertise.”

The Robert Koch Foundation states: “With his research, Professor Winnacker contributed significantly to the description of life processes at molecular level and therefore to the development of molecular biology and genetic engineering. As a result of his many years as a member of numerous different research associations and committees, he has had a significant bearing on international research in the field of life science research, as well as on policy-making in this field. His position also allowed him to provide invaluable impulses to the sustainable development of the German and European scientific system.”

Under the patronage of the German Federal President Christian Wulff, the Robert Koch Foundation promotes medical science and research in the field of infectious and other widespread diseases. The foundation awards the Robert Koch Prize for outstanding, internationally recognized scientific achievements and the Robert Koch Medal in Gold.

This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the forward-looking statements made herein. MediGene is not bound to update any of these forward-looking statements. MediGene® is a registered trademark of MediGene AG. This trademark may be owned or licensed in select locations only.

- ends -

MediGene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology company headquartered in Martinsried/Munich, Germany. MediGene is the first German biotech company to have revenues from marketed products. It has various drug candidates in clinical development and possesses innovative platform technologies. MediGene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases.

Contact MediGene AG

Julia Hofmann, Kerstin Langlotz
Investor & Public Relations
Tel.: +49 - 89 - 85 65 - 33 01
Fax: +49 - 89 - 85 65 - 29 20
Email: investor@medigene.com